Social value of statins merits actions to broaden treatment, improve adherence, study finds
News
Article
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
Social value of statins merits actions to broaden treatment, improve adherence, study finds
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
Novo Nordisk Offers Wegovy Through Telehealth Providers, Including Hims & Hers
Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg through its NovoCare Pharmacy.
Read More
Food Retailer Giant Eagle Selects EmpiRx Health as PBM
Giant Eagle also helped EmpiRx Health create a national pharmacy care network that was purpose-built for pharmacy and grocery chains.
Read More
Part D Plans Cover a Larger Share of Medicare Beneficiaries in Rural Counties
Nationwide, 58% of Medicare beneficiaries living in rural areas are enrolled in stand-alone prescription drug plans in 2025.
Read More
FDA Issues CRL for Extended Dosing of Eylea HD
The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.
Read More
FDA Approves Dupixent for Inflammatory Skin Disease
Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.
Read More
FDA Sets Action Date for Eylea HD in Retinal Vein Occlusion
If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.
Read More
Novo Nordisk Offers Wegovy Through Telehealth Providers, Including Hims & Hers
Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg through its NovoCare Pharmacy.
Read More
Food Retailer Giant Eagle Selects EmpiRx Health as PBM
Giant Eagle also helped EmpiRx Health create a national pharmacy care network that was purpose-built for pharmacy and grocery chains.
Read More
Part D Plans Cover a Larger Share of Medicare Beneficiaries in Rural Counties
Nationwide, 58% of Medicare beneficiaries living in rural areas are enrolled in stand-alone prescription drug plans in 2025.
Read More
FDA Issues CRL for Extended Dosing of Eylea HD
The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.
Read More
FDA Approves Dupixent for Inflammatory Skin Disease
Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.
Read More
FDA Sets Action Date for Eylea HD in Retinal Vein Occlusion
If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.
Read More